Novo Nordisk A/S (NYSE:NVO) Receives Average Rating of "Hold" from Brokerages

Key Points

• Analyst consensus: 24 brokerages give Novo Nordisk an average rating of Hold (1 sell, 19 hold, 4 buy) with a mean 12‑month price target of $65.56.
• Recent results beat expectations—Q: $1.01 EPS vs. $0.90 est. and $12.43B revenue vs. $11.97B—and the stock trades well below its 52‑week high (opened at $36.92; 52‑week range $35.12–$81.44) with a PE of 10.64.
• Outlook is mixed: commercial and regulatory wins for Wegovy (NICE recommendation, subscription pricing, favorable oral data) support demand, but FDA approval of Eli Lilly’s oral GLP‑1 and potential drug import tariffs present material competitive and policy risks.

Shares of Novo Nordisk A/S (NYSE:NVO - Get Free Report) have been assigned an average rating of "Hold" from the twenty-four brokerages that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, nineteen have given a hold rating and four have issued a buy rating on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $65.5625.

Several equities research analysts have recently commented on the stock. Argus reaffirmed a "hold" rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. HSBC reissued a "hold" rating and issued a $54.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, December 10th. Kepler Capital Markets lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Tuesday, February 24th. CICC Research started coverage on Novo Nordisk A/S in a research report on Friday, January 9th. They set an "outperform" rating and a $73.50 price objective on the stock. Finally, Jefferies Financial Group upgraded Novo Nordisk A/S from an "underperform" rating to a "hold" rating in a report on Thursday, February 12th.

Hedge Funds Weigh In On Novo Nordisk A/S

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. True Wealth Design LLC grew its position in shares of Novo Nordisk A/S by 209.8% in the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company's stock worth $25,000 after buying an additional 300 shares during the period. Guerra Advisors Inc purchased a new position in Novo Nordisk A/S during the 3rd quarter valued at about $25,000. Godfrey Financial Associates Inc. bought a new stake in Novo Nordisk A/S during the fourth quarter worth about $25,000. WealthCollab LLC boosted its stake in Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company's stock worth $27,000 after acquiring an additional 260 shares in the last quarter. Finally, American National Bank & Trust purchased a new stake in Novo Nordisk A/S in the fourth quarter worth about $28,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Price Performance

NVO opened at $36.92 on Friday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. The stock has a market capitalization of $164.86 billion, a PE ratio of 10.64, a price-to-earnings-growth ratio of 8.63 and a beta of 0.73. The stock's 50 day moving average price is $43.93 and its 200-day moving average price is $49.98. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $81.44.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.11. The business had revenue of $12.43 billion for the quarter, compared to analysts' expectations of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. On average, equities research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Dividend Announcement

The company also recently declared a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be paid a $1.2751 dividend. This represents a yield of 723.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S's dividend payout ratio is presently 50.43%.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: U.K. drug regulator NICE recommended Wegovy for heart‑disease prevention, expanding NHS access by about 1.2 million people — a material commercial win that supports longer‑term demand for Wegovy. Novo Nordisk shares rise after Wegovy recommended by Britain's drug price regulator
• Positive Sentiment: Management launched a Wegovy subscription pricing model and expanded telehealth partnerships to lower out‑of‑pocket costs and improve adherence — a tactical move to protect market share and pricing power in self‑pay segments. NVO Launches Wegovy Subscription Plan, Boosts Access, Stock Up
• Positive Sentiment: Novo released a cross‑trial comparison (ORION) showing oral Wegovy produced greater mean weight loss and fewer dropouts versus Lilly’s pill — messaging aimed at bluntly defending the oral franchise as Lilly begins commercialization. Novo Nordisk says Wegovy pill outperforms Lilly's oral GLP-1 in cross-trial comparison
• Positive Sentiment: Pipeline progress continues: Novo is advancing next‑generation metabolic candidates (including a triple‑agonist program) through early clinical trials, which supports longer‑term upside beyond current GLP‑1 competition. Novo Nordisk Triple Agonist Progress Spurs Questions On Valuation Gap
• Neutral Sentiment: BMO Capital reiterated a Market Perform (hold) rating with a $45 price target — signaling analysts see limited near‑term upside while acknowledging the Wegovy pill momentum. BMO Capital Maintains a Hold Rating on Novo Nordisk (NVO)
• Neutral Sentiment: Market coverage notes the shares edged higher and held up early despite Lilly’s approval — suggesting investors had partially priced in competitive pressure. Novo Nordisk shares resilient as FDA approves Eli Lilly GLP-1 weight-loss pill to intensify competition
• Negative Sentiment: FDA approval of Eli Lilly’s oral GLP‑1 (Foundayo/orforglipron) and an expected multi‑billion dollar commercial debut create direct pricing and market‑share pressure on Novo’s Wegovy/Ozempic franchises. Analysts and traders are pricing a more contested oral market going forward. Wall Street sees multi-billion dollar debut for Lilly's obesity pill despite Novo lead
• Negative Sentiment: Broader policy/regulatory risk: reports the administration is considering tariffs of up to 100% on branded drug imports could create volatility and uncertainty for multinational drugmakers if no concessions/deals are struck. Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs
• Negative Sentiment: Analyst commentary highlights intensifying duopoly dynamics with Eli Lilly, product gaps in injectables vs. Lilly, and patent/competitive lifecycle concerns — risks that could pressure growth and valuation if market share slips. Novo Nordisk: Competing In A Duopoly

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.